Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update
The proposed rescheduling of cannabis to Schedule III represents a regulatory milestone that could unlock rigorous clinical research previously restricted under Schedule I classification. This change would enable pharmaceutical-grade development pathways…
Texas Hemp Businesses Sue Over State Rules That Rewrite Law
The texas hemp regulatory lawsuit addresses new state rules that rewrite existing hemp laws. This legal dispute affects hemp-derived CBD product availability. Patients and businesses face uncertainty due to these regulatory challenges.
Avicanna Strengthens Board as It Targets Global Cannabinoid Growth
Avicanna cannabinoid therapeutics board expansion signals a strategic push in global cannabinoid product development. The company focuses on plant-derived cannabinoid therapeutics within regulated pharmaceutical frameworks. This development highlights…
5 Exciting Insights from the MedCan 3 Trial
MedCan 3: A Landmark Study on Medicinal Cannabis for Cancer Symptom Management Read The Study Publication The MedCan 3 study is a highly anticipated clinical trial investigating the potential of medicinal cannabis to alleviate symptoms in…